Clinical-pathological Characteristics, Survival Outcomes, and Prognostic Factors of Stage I Ovarian Endometrioid Carcinoma: A SEER-based Study

Jing Zhu, Pingyue Yu, Yuwen Weng, Haili Li^*

Shenzhen People’s Hospital, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shen-zhen, Guangdong, China.

*Corresponding author: Haili Li

Published: 20 June 2024 How to cite this paper

Abstract

Objective: To identify the factors that predict survival in patients with Stage I ovarian endometrioid carcinoma and to determine whether lymph node dissection treatment can improve survival rates. Methods: Clinical information for patients with Stage I ovarian endometrioid cancer from 2004 to 2015 was obtained from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariate Cox analyses were used to identify independent prognostic factors, with patients categorized into subgroups based on lymph node dissection (defined as the removal of more than four lymph nodes). Kaplan-Meier curves were used to compare survival rates between the subgroups. Results: A total of 3,659 patients with Stage I ovarian endometrioid carcinoma were included, 1,247 (34.1%) underwent resection of fewer than four lymph nodes, while 2,412 (65.9%) underwent resection of four or more lymph nodes. The mean follow-up duration was 91.99 months. In the multivariate Cox analysis, lymphadenectomy, age, grade, tumor size, and chemotherapy were significant predictors of survival outcomes (P < 0.05). Patients who underwent resection of more than four lymph nodes and received adjuvant chemotherapy, along with those who were younger, had well-differentiated tumors, had smaller tumor sizes, and showed higher overall survival rates. Conclusion: Lymphadenectomy can improve the overall survival rate of patients with Stage I ovarian endometrioid carcinoma.

KEYWORDS: Ovarian endometrioid carcinoma, SEER, lymph node dissection, prognosis

References

[1] Long M E, Taylor H C. Endometrioid Carcinoma of the Ovary [J]. American Journal of Obstetrics and Gynecology, 1964, 90: 936-950.

[2] Torre L A, Trabert B, Desantis C E, et al. Ovarian cancer statistics, 2018 [J]. CA: A Cancer Journal for Clinicians, 2018, 68(4): 284-296.

[3] Imterat M, Bizzarri N, Fruscio R, et al. Impact of substage and histologic type in stage I ovarian carcinoma survival: a multicenter retrospective observational study [J]. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, 2023, 33(1): 42-49.

[4] Kajiyama H, Suzuki S, Yoshihara M, et al. Endometriosis and cancer [J]. Free Radical Biology & Medicine, 2019, 133: 186-192.

[5] Ran X, Jing H, Li Z. The clinical features and management of Lynch syndrome-associated ovarian cancer [J]. The Journal of Obstetrics and Gynaecology Research, 2022, 48(7): 1538-1545.

[6] Zaino R J, Unger E R, Whitney C. Synchronous carcinomas of the uterine corpus and ovary [J]. Gynecologic Oncology, 1984, 19(3): 329-335.

[7] Padhy R R, Savage J, Kurman R J. Comprehensive Surgical Staging in Stage 1 Clear Cell and Endometrioid Ovarian Carcinomas: Is it Necessary? [J]. International Journal of Gynecological Pathology: Official Journal of the International Society of Gynecological Pathologists, 2019, 38(3): 241-246.

[8] Colombo N, Sessa C, Bois A du, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease [J]. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, 2019: ijgc-2019-000308.

[9] Minig L, Heitz F, Cibula D, et al. Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study [J]. Annals of Surgical Oncology, 2017, 24(9): 2720-2726.

[10] Heitz F, Harter P, Ataseven B, et al. Stage- and Histologic Subtype-Dependent Frequency of Lymph Node Metastases in Patients with Epithelial Ovarian Cancer Undergoing Systematic Pelvic and Paraaortic Lymphadenectomy [J]. Annals of Surgical Oncology, 2018, 25(7): 2053-2059.

[11] Bizzarri N, Imterat M, Fruscio R, et al. Lymph node staging in grade 1-2 endometrioid ovarian carcinoma apparently confined to the ovary: Is it worth? [J]. European Journal of Cancer (Oxford, England: 1990), 2023, 195: 113398.

[12] Lorusso D, Pignata S. Role of adjuvant chemotherapy in early-stage endometrioid and clear-cell ovarian cancer [J]. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2017, 28(12): 2909-2911.

[13] Chen J, Yin J, Li Y, et al. Systematic Lymph Node Dissection May Be Abolished in Patients with Apparent Early-Stage Low-Grade Mucinous and Endometrioid Epithelial Ovarian Cancer [J]. Frontiers in Oncology, 2021, 11: 705720.

[14] Storey D J, Rush R, Stewart M, et al. Endometrioid epithelial ovarian cancer: 20 years of prospectively collected data from a single center [J]. Cancer, 2008, 112(10): 2211-2220.

[15] Wang S, Qiu L, Lang J H, et al. Prognostic analysis of endometrioid epithelial ovarian cancer with or without endometriosis: a 12-year cohort study of Chinese patients [J]. American Journal of Obstetrics and Gynecology, 2013, 209(3): 241.e1-9.

[16] Grosso G, Raspagliesi F, Baiocchi G, et al. Endometrioid carcinoma of the ovary: a retrospective analysis of 106 cases [J]. Tumori, 1998, 84(5): 552-557.

[17] Chan J K, Teoh D, Hu J M, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers [J]. Gynecologic Oncology, 2008, 109(3): 370-376.

[18] Kumar A, Le N, Tinker A V, et al. Early-stage endometrioid ovarian carcinoma: population-based outcomes in British Colum-bia[J]. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, 2014, 24(8): 1401-1405.

[19] Nasioudis D, Chapman-Davis E, Witkin S S, et al. Prognostic significance of lymphadenectomy and prevalence of lymph node metastasis in clinically-apparent stage I endometrioid and mucinous ovarian carcinoma [J]. Gynecologic Oncology, 2017, 144(2): 414-419.

[20] Swift B E, Covens A, Mintsopoulos V, et al. The effect of complete surgical staging and adjuvant chemotherapy on survival in stage I, grade 1 and 2 endometrioid ovarian carcinoma [J]. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, 2022, 32(4): 525-531.

[21] Yoshihara M, Tamauchi S, Iyoshi S, et al. Impact of incomplete surgery and adjuvant chemotherapy for the intraoperative rupture of capsulated stage I epithelial ovarian cancer: a multi-institutional study with an in-depth subgroup analysis [J]. Journal of Gynecologic Oncology, 2021, 32(5): e66.

[22] Zhao Y, Wang S, Qu Y-M, et al. Prognostic analysis for Chinese patients with stage I ovarian endometrioid carcinoma [J]. Journal of Ovarian Research, 2017, 10(1): 63.

[23] Zhou L, Yao L, Dai L, et al. Ovarian endometrioid carcinoma and clear cell carcinoma: A 21-year retrospective study [J]. Journal of Ovarian Research, 2021, 14(1): 63.

[24] Moro F, Magoga G, Pasciuto T, et al. Imaging in gynecological disease (13): clinical and ultrasound characteristics of endometri-oid ovarian cancer [J]. Ultrasound in Obstetrics & Gynecology: The Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology, 2018, 52(4): 535-543.

[25] De Nonneville A, Zemmour C, Frank S, et al. Clinicopathological characterization of a real-world multicenter cohort of endome-trioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database [J]. Gynecologic Oncology, 2021, 163(1): 64-71.

[26] Ye W, Wang Q, Lu Y. Construction and validation of prognostic nomogram and clinical characteristics for ovarian endometrioid carcinoma: An SEER-based cohort study [J]. Journal of Cancer Research and Clinical Oncology, 2023, 149(15): 13607-13618.

[27] Lim M C, Chun K-C, Shin S-J, et al. Clinical presentation of endometrioid epithelial ovarian cancer with concurrent endometriosis: a multicenter retrospective study [J]. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2010, 19(2): 398-404.

[28] Kline R C, Wharton J T, Atkinson E N, et al. Endometrioid carcinoma of the ovary: retrospective review of 145 cases [J]. Gynecologic Oncology, 1990, 39(3): 337-346.

[29] Malkasian G D, Melton L J, O’Brien P C, et al. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary [J]. American Journal of Obstetrics and Gynecology, 1984, 149(3): 274-284.

[30] Li S, Zhu Z. Chemotherapy is not necessary for early-stage serous and endometrioid ovarian cancer after undergoing comprehensive staging surgery [J]. Journal of Ovarian Research, 2020, 13(1): 91.

How to cite this paper

Jing Zhu, Pingyue Yu, Yuwen Weng, Haili Lin. Clinical-pathological Characteristics, Survival Outcomes, and Prognostic Factors of Stage I Ovarian Endometrioid Carcinoma: A SEER-based Study. International Journal of Medicine Frontiers, 2024, 7(1), 24-34.

Recommended Reading

Clinical-pathological Characteristics, Survival Outcomes, and Prognostic Factors of Stage I Ovarian Endometrioid Carcinoma: A SEER-based Study

Abstract

References

How to cite this paper